drugset
drugset / Trial / NCT06092645

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

NCT06092645 ↗

Phase 2 Unknown 48 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct adenocarcinoma

Timeline

Start
2023-10-30
Primary completion
2024-10-01
Completion
2025-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg Intravenous
Subject Surufatinib Small molecule 250 mg Oral

Indications

bile duct adenocarcinoma